Greenlight Biosciences

What Greenlight Biosciences does

GreenLight Biosciences is a publicly traded Public Benefit Corporation (PBC) that develops RNA-based agricultural and animal health products, built around a proprietary cell-free dsRNA manufacturing platform. The company's core technology produces Technical Grade Active Ingredient (TGAI) double-stranded RNA at less than $1/gram using a clean enzymatic, cell-free process that regenerates energy via polyphosphates and thermally stable enzymes, a cost point the company states is unattainable via conventional IVT or cell-based fermentation. Its commercial portfolio comprises Calantha (EPA-registered bio-insecticide for Colorado Potato Beetle, additionally granted Belgian Emergency Use Authorization for the 2026 growing season), Norroa (EPA-registered RNA-based Varroa destructor mite treatment for honeybees, launched September 2025), and Fortivance (RNA enhancer adjuvant currently sold in Brazil). The platform also underwrites a regulatory-stage pipeline that includes RNA-based fungicides for grape powdery mildew, a multi-species mite product, and a soybean cyst nematode solution funded by a USDA NIFA SBIR grant.

The company's go-to-market operates on an enterprise field-sales motion directed at commercial potato growers, commercial beekeepers, and increasingly Brazilian and European agribusiness customers, with product sales augmented by R&D partnerships and licensing arrangements with universities and corporate partners. Manufacturing is anchored at a 17,000-square-foot Rochester, NY facility described as the world's largest RNA plant by volume, with current commercial capacity of 5.2 metric tons per year scalable to more than 50 MT. Founded in 2008, headquartered in Medford, MA, GreenLight became public via a SPAC merger at a $1.5 billion valuation; it subsequently raised approximately $109 million in private placement proceeds in August 2022, a €35 million EIB loan in February 2025, and a $25 million Just Climate strategic investment in March 2025 to fund a Brazilian subsidiary headquartered in Piracicaba. R&D operations also extend to a research center in Seville, Spain, operated through GreenLight Biosciences España.

Name

Greenlight Biosciences

Legal name

GreenLight Biosciences, Inc.

Website

https://greenlightbiosciences.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

GreenLight Biosciences develops RNA-based crop protection and animal health products using a proprietary cell-free dsRNA manufacturing platform. It sells EPA-registered bio-insecticides, miticides, and adjuvants to commercial potato growers, beekeepers, and agricultural operators in the US, EU, and Brazil.

Ownership category

akta.pro rank

Product category

Agricultural Biotechnology / RNA-based Crop Protection

NAICS

Pesticide and Other Agricultural Chemical Manufacturing (32532)

SIC

Agricultural Chemicals (2870)

akta.pro primary industry

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

akta.pro secondary industry

Crop Protection Chemicals (Herbicides/Insecticides/Fungicides) (IMAEAEAI)

Keywords

• RNA biopesticides
• Crop protection products
• Agricultural biotechnology
• Honeybee health
• Cell-free RNA manufacturing

Headquarters

HQ city

Medford

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product sales - Calantha: Commercial sale of Calantha™ (foliar RNA bio-insecticide powered by ledprona) for Colorado Potato Beetle control in potato crops. EPA-registered in the United States; under Emergency Use Authorization in Belgium (May–August 2026); under review in other key markets. Mixed with water and applied with standard agricultural spray equipment at less than one-tenth the rate of many conventional chemicals.
2. Product sales - Norroa: Commercial sale of Norroa™ (active ingredient vadescana), the first EPA-registered RNA-based treatment for Varroa destructor mites in honey bee colonies. Sold through norroa.com to commercial beekeepers in the U.S. Designed to be placed in pouches inside hives for bees to consume.
3. Product sales - Fortivance: Commercial sale of Fortivance™, an RNA-based enhancer adjuvant for insecticides, currently being sold in Brazil via the company's Piracicaba HQ operations.
4. Future RNA-based fungicide for grape powdery mildew: RNA-based fungicide targeting Erysiphe necator (grape powdery mildew) has had regulatory dossiers submitted in the U.S., EU, and Brazil; plans to file in Argentina and Chile. Designed to be compatible with existing farm practices, applied throughout the crop cycle with no special equipment needed. Future recurring product revenue.
5. R&D partnership and licensing revenue: Collaborations with leading universities, companies, and scientists (e.g., academic research institutions, strategic corporate partners) where GreenLight provides its platform access for validating research and accelerating production; partner receives cell-free RNA production capabilities while GreenLight receives co-development and commercial milestones.

Pricing tiers

Go-to-market motion1 record

Core offering

GreenLight Biosciences develops and commercializes RNA-based agricultural and animal health products using a proprietary cell-free RNA manufacturing platform. Its commercial products include Calantha (ledprona), a foliar RNA bio-insecticide for Colorado Potato Beetle control in potatoes, and Norroa (vadescana), the first EPA-registered RNA-based Varroa destructor mite treatment for honeybees. The company also sells Fortivance, an RNA-based enhancer adjuvant, in Brazil and is building a pipeline of RNA-based fungicides, miticides, and nematicides for sustainable crop protection.

Product overview

GreenLight Biosciences operates as a platform-plus-products architecture: a proprietary cell-free RNA manufacturing platform (the GreenLight Bio Platform) serves as the production engine for a portfolio of branded RNA-based crop protection products. The platform is engineered to produce double-stranded RNA at low cost and high quality, enabling commercial-scale agricultural RNAi solutions. Branded products sit on top of this platform: Calantha (insecticide for Colorado Potato Beetle, first-ever EPA-registered RNA crop protection product), Norroa (RNA-based Varroa mite treatment for honeybees, containing vadescana), and Fortivance (an enhancer adjuvant used in conjunction with insecticides, deployed in Brazil). The platform also underpins a regulatory-stage pipeline that includes an RNA-based grape powdery mildew solution, a multi-species mite product, and research-stage work on soybean cyst nematode, fall armyworm, and diamondback moth.

Differentiator

Problem solved

Functional benefit

Brands

• Calantha: RNA-based bio-insecticide (powered by ledprona) approved by the U.S. EPA for control of Colorado Potato Beetles in potato crops; also granted Belgian Emergency Use Authorization for the 2026 growing season.
• Norroa
• Fortivance

Products and services

• Calantha (ledprona)
• Norroa (vadescana)
• Fortivance

Quantifiable outcome

• Reduces pesticide use rate to 9.9 g/hectare for Colorado Potato Beetle control - described as 'a spoonful of sugar spread on a football field', less than one-tenth of many conventional industrial chemicals
• +7 more outcomes

Named customers1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core channel partner (belgium), strategic grant/program partner, key academic research partner, major prior asset partner, key in-country stakeholder and regulatory relationship (public company filings).

• Fine Agrochemicals B.V. (De Sangosse Group)core channel partner (belgium)Channel Partner/ Reseller/ DistributorCollaborating with GreenLight Biosciences to support Calantha product deployment, technical guidance, and stewardship throughout the Belgian Emergency Use Authorization period (May 1 - August 28, 2026). Leverages Fine B.V.'s strong presence in the potato segment to ensure Belgian growers have access to local expertise and support as they implement this new mode of action.
• Bill & Melinda Gates Foundationstrategic grant/program partnerStrategic or Co-development PartnerReached a Bill & Melinda Gates milestone - referenced in the 'Where we are now' page as part of the company's foundational work to enable equitable access to RNA-based agricultural solutions in low- and middle-income countries. Foundation relationship is tied to advancing agricultural solutions for underserved farming communities.
• Victoria University of Wellingtonkey academic research partnerStrategic or Co-development PartnerResearchers at Victoria University of Wellington developed the double-stranded RNA technology targeting the Varroa destructor mite, which is now produced commercially by GreenLight Biosciences Inc as the active ingredient vadescana in Norroa. Academic-to-commercial research partnership that GreenLight has scaled globally.
• Bayermajor prior asset partnerStrategic or Co-development PartnerGreenLight acquired Bayer's topical RNA honeybee treatment in December 2020 and subsequently advanced it through development and secured EPA registration of Norroa in September 2025. The acquired asset became GreenLight's Norroa™ (vadescana) product line.
• Belgapom (Belgian potato growers association)key in-country stakeholderGTM or Marketing PartnerBelgapom and other Belgian potato grower stakeholders supported GreenLight's Emergency Use Authorization application for Calantha in Belgium, the first RNA-based crop-protection use in the EU. Belgapom represents the Belgian potato industry and coordinated grower demand behind the authorization request.
• U.S. Securities and Exchange Commission (SEC)regulatory relationship (public company filings)OthersGreenLight Biosciences, Inc. is a registered SEC filer (CIK 0001822691); the company maintains historic SEC filings accessible via EDGAR, reflecting its status as a publicly traded Public Benefit Corporation following its SPAC merger.

Scale indicators11 records

Recent moves3 records

Direct peers

• Vestaron: U.S. biopesticide company commercializing peptide-based insecticides with novel modes of action against pests including CPB and spider mites. Closest direct peer to GreenLight by virtue of selling biologically derived, novel-mechanism crop protection products into the same specialty and row-crop grower channels.
• AgBiome: U.S. microbial crop protection company building a pipeline of biological fungicides, insecticides, and nematicides from a curated microbial collection. Comparable to GreenLight as a biological-input developer with multiple SKUs targeting the same grower segments and resistance-management use cases.
• Marrone Bio Innovations: Commercial-stage biopesticide company (now part of Bioceres Crop Solutions) marketing biological crop protection and plant health products globally. Comparable to GreenLight as a multi-product biologicals seller with established distribution and regulatory dossiers in the same row-crop and specialty-crop markets.
• Certis Biologicals: Specialty biologicals division that sells biopesticides and biofungicides derived from microbial and botanical sources to growers worldwide. Comparable to GreenLight as a competing biological-input brand fighting for shelf space in distribution with conventional chemistry.

Broad incumbents

• Corteva: Global seed-and-crop-protection major with the Conservo RNAi-based corn rootworm trait in market. Comparable to GreenLight as an agricultural RNAi competitor with vastly greater distribution, capital, and grower relationships that could commoditize foliar RNAi applications.
• Bayer Crop Science: Global agribusiness with significant RNAi programs (e.g., SmartStax PRO) and the prior owner of the honeybee RNAi asset GreenLight acquired in December 2020. Comparable as a deep-pocketed incumbent that could re-enter the foliar/adjacent RNAi categories where GreenLight currently leads.
• Syngenta Group: Global agribusiness with publicly funded RNAi programs (post-Devgen acquisition) and broad seed-and-chemical distribution. Comparable to GreenLight as an incumbent with the channels and capital to scale RNAi-based solutions into the same row-crop markets GreenLight is targeting.
• BASF Agricultural Solutions: Global agribusiness with a growing biologicals portfolio and active RNAi R&D. Comparable to GreenLight as a broad incumbent that can bundle biological solutions with conventional chemistry and erode standalone biologicals pricing.

Regional players

• Bioceres Crop Solutions: Latin American agricultural inputs company (and acquirer of Marrone Bio Innovations) with deep distribution across Brazil, Argentina, and the Mercosur region. Comparable to GreenLight as a peer now operating in the same geographies where GreenLight is building its Brazilian HQ and pursuing Argentina/Chile registrations.

Emerging players

• BioConsortia: U.S. ag-biotech startup developing microbial and trait-based crop solutions, including nitrogen-fixation and pest-control products. Comparable to GreenLight as an emerging biologicals platform pursuing multiple agricultural pest and disease targets through a single R&D engine.

Market position

Strengths5 records

Weaknesses5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/GreenLightBio1
• LinkedInlinkedin.com/company/greenlight-biosciences-inc.

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors36 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenlight Biosciences